JP2019530739A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530739A5
JP2019530739A5 JP2019532215A JP2019532215A JP2019530739A5 JP 2019530739 A5 JP2019530739 A5 JP 2019530739A5 JP 2019532215 A JP2019532215 A JP 2019532215A JP 2019532215 A JP2019532215 A JP 2019532215A JP 2019530739 A5 JP2019530739 A5 JP 2019530739A5
Authority
JP
Japan
Prior art keywords
pyridin
trifluoromethyl
sulfonamide
chloro
sulfamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530739A (ja
JP7035055B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/055162 external-priority patent/WO2018042316A1/en
Publication of JP2019530739A publication Critical patent/JP2019530739A/ja
Publication of JP2019530739A5 publication Critical patent/JP2019530739A5/ja
Application granted granted Critical
Publication of JP7035055B2 publication Critical patent/JP7035055B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532215A 2016-08-29 2017-08-28 N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用 Expired - Fee Related JP7035055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380659P 2016-08-29 2016-08-29
US62/380,659 2016-08-29
PCT/IB2017/055162 WO2018042316A1 (en) 2016-08-29 2017-08-28 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Publications (3)

Publication Number Publication Date
JP2019530739A JP2019530739A (ja) 2019-10-24
JP2019530739A5 true JP2019530739A5 (enExample) 2020-08-27
JP7035055B2 JP7035055B2 (ja) 2022-03-14

Family

ID=59923496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019532215A Expired - Fee Related JP7035055B2 (ja) 2016-08-29 2017-08-28 N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体および疾患の処置におけるそれらの使用

Country Status (15)

Country Link
US (2) US10450273B2 (enExample)
EP (1) EP3504194B1 (enExample)
JP (1) JP7035055B2 (enExample)
KR (1) KR20190040319A (enExample)
CN (1) CN109641873B (enExample)
AR (1) AR109437A1 (enExample)
AU (1) AU2017319430A1 (enExample)
BR (1) BR112019003883A2 (enExample)
CA (1) CA3031073A1 (enExample)
EA (1) EA201990609A1 (enExample)
ES (1) ES2898069T3 (enExample)
MX (1) MX2019002439A (enExample)
TW (1) TW201811766A (enExample)
UY (1) UY37379A (enExample)
WO (1) WO2018042316A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
KR102825974B1 (ko) 2016-09-13 2025-06-30 삼성디스플레이 주식회사 표시 장치
EP3844158A1 (en) * 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN113226464A (zh) * 2018-12-18 2021-08-06 诺华股份有限公司 N-(吡啶-2-基磺酰基)环丙烷甲酰胺衍生物及其在治疗cftr介导的疾病中的用途
US20220071971A1 (en) * 2018-12-21 2022-03-10 Novartis Ag Macrocyclic compounds and their use in the treatment of disease
CN113423702A (zh) * 2019-02-06 2021-09-21 诺华股份有限公司 N-(吡啶-2-基)吡啶-磺酰胺衍生物及其在治疗疾病中的用途
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
TWI867024B (zh) * 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
HRP20240606T1 (hr) 2019-08-14 2024-07-19 Vertex Pharmaceuticals Incorporated Postupak za proizvodnju modulatora za cftr
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
WO2021097057A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
IL292965A (en) * 2019-11-12 2022-07-01 Genzyme Corp 6-membered heteroarylaminosulfonamides and methods of use
JP2023509584A (ja) * 2019-12-13 2023-03-09 ローディア オペレーションズ ベンゼン誘導体の製造
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
IL303519A (en) 2020-12-10 2023-08-01 Vertex Pharma Cystic fibrosis treatment methods

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5939431A (en) * 1996-06-20 1999-08-17 Schering Corporation Naphthyridines which affect IL-4 and G-CSF
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
ATE454378T1 (de) 2002-11-01 2010-01-15 Vertex Pharma Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US20070099938A1 (en) 2003-10-24 2007-05-03 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
MXPA06012130A (es) 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
US7544702B2 (en) 2004-08-12 2009-06-09 Amgen Inc. Bisaryl-sulfonamides
KR100874313B1 (ko) 2004-10-04 2008-12-18 에프. 호프만-라 로슈 아게 당뇨병을 치료하기 위한 11-베타 억제제로서의 알킬-피리딘
EP1666467A1 (en) 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
CA2620179C (en) 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
CA2620257A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
CN101484452A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
EP2049515B1 (en) 2006-07-14 2011-01-26 ChemoCentryx, Inc. Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
DK2420494T3 (en) 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
KR20090060333A (ko) 2006-09-08 2009-06-11 노파르티스 아게 림프구 상호작용에 의해 매개되는 질환의 치료에 유용한 n-바이아릴 (헤테로)아릴술폰아미드 유도체
WO2008033455A2 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
ES2594704T3 (es) 2007-04-11 2016-12-22 Canbas Co., Ltd. Compuestos con actividad anticancerosa
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
JP2011511056A (ja) 2008-02-05 2011-04-07 ファイザー・インク Cns障害および代謝障害治療のためのピリジニルアミド
US20110144107A1 (en) 2008-06-11 2011-06-16 Irm Llc Compounds and compositions useful for the treatment of malaria
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
CN102458122A (zh) * 2009-04-20 2012-05-16 人类健康研究所 含有哒嗪磺胺衍生物的化合物、组合物和方法
EP2253617A1 (de) 2009-05-20 2010-11-24 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
MX2013000188A (es) 2010-06-28 2013-01-28 Bayer Ip Gmbh Compuestos heterociclicos como pesticidas.
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
AU2011346751A1 (en) 2010-12-22 2013-05-02 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2012125904A1 (en) 2011-03-17 2012-09-20 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of egfr
WO2013038390A1 (en) * 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
CA2881357C (en) 2012-08-21 2020-12-08 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
US20140073634A1 (en) 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
JP2017503772A (ja) 2013-12-23 2017-02-02 ノージン ビーブイ Ccr9阻害剤としてのベンゼンスルホンアミド
CA2942387A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
CN104844566B (zh) 2014-12-12 2018-05-18 合肥中科普瑞昇生物医药科技有限公司 一种新型结构的激酶抑制剂
HK1253581A1 (zh) * 2015-06-02 2019-06-21 Abbvie S.A.R.L. 经取代的吡啶及使用方法
US9981945B2 (en) * 2015-10-07 2018-05-29 NuBridge BioSciences Pyrimidine derivatives as CFTR modulators
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途

Similar Documents

Publication Publication Date Title
JP2019530739A5 (enExample)
US11129832B2 (en) Biheteroaryl compounds and uses thereof
RU2484091C2 (ru) Производные изоксазоло-пиридина
AU2018204431B2 (en) Compounds useful as inhibitors of ATR kinase
JP5788415B2 (ja) Cdk4/6阻害剤としてのピロロピリミジン化合物
CA2900855C (en) Aminopyrimidinyl compounds
JP2017524007A5 (enExample)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
ES2637588T3 (es) Nuevos compuestos tricíclicos
US20230233692A1 (en) Compounds for targeted degradation of ret
JP2021506858A5 (enExample)
JP2019535664A5 (enExample)
JP2017505327A5 (enExample)
JP2018500376A5 (enExample)
JP2013515070A5 (enExample)
GB2609879A (en) Antagonists of the adenosine A2a receptor
EP2548877A1 (en) 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JPWO2021076602A5 (enExample)
AU2014347026A1 (en) Substituted pyridine derivatives useful as GSK-3 inhibitors
HRP20210285T1 (hr) Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka
JP2015512427A5 (enExample)
JPWO2022208269A5 (enExample)
US20240360134A1 (en) Pyrazolopyrimidines and their uses as pdgfr inhibitors
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof